Indian Peptic Ulcer drugs market size stood at USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of XX% during the forecast period 2019-2028.
Peptic ulcer drugs are used to treat erosion of the gastrointestinal lining due to a variety of factors. Peptic ulcer is the result of an imbalance between aggressive and defensive fluids in the stomach. Peptic ulcer includes gastric, esophageal and duodenal ulcer. The duodenal to gastric ulcer ratio was 17.1:1. Duodenal and gastric ulcer were common in men. The factors such as growing prevalence of stress-induced ulcers due to changing lifestyle and diet, increasing smoking rate, and progressive population of geriatrics are anticipated to promote the expansion of the Indian peptic ulcer drugs market size over the forecast period 2019-2028.
The major driving factors for peptic ulcers drug market are stress, drug induced ulcers, growing rate of infection by H.Pyrroli, changes in food, rise in cancer, tobacco and alcohol use. Constraining factors of this market are patent expiry, comparatively good treatment regimen of proton pump inhibitors, resistance of H.Pyrolli, extreme market fragmentation into many companies and great penetration of generics. Increasing preference for peptic ulcer drugs over surgical methods for the treatment of PUD is expected to propel growth of the Indian peptic ulcer drugs market over the forecast period. This is attributed to complex issues involved in surgical management and post-surgical complications of peptic ulcer.